Cost-minimization analysis of joint venture entecavier and domestic entecavier in treating patients with chronic hepatitis B
-
摘要: 目的 探讨合资、国产恩替卡韦治疗慢性乙型肝炎的有效性及经济性。 方法 回顾性分析本院专家门诊2009年10月~2010年10月治疗的慢性乙型肝炎患者65例, A组33例,给予合资恩替卡韦,0.5 mg,口服1次/d;B组32例,给予国产恩替卡韦,0.5 mg,口服1次/d。治疗48周观察疗效,并采用最小成本法分析。 结果 在ALT复常率、HBV-DNA转阴率和HBeAg血清转换率等效果方面,两组差异无显著性意义(P>0.05),A组成本为12 028.8元;B组成本为7 996.8元。 结论 国产恩替卡韦治疗慢性乙型肝炎的最小成本优于合资恩替卡韦。Abstract: Objective To study the validity and affordability between joint venture entercavier and domestic entercavier in treating patients with chronic hepatitis B. Methods 65 patients with chronic hepatitis B were select who were treated with entercavier between Oct. 2009 to Oct.2010 in Ningbo No. 2 Hospital expert outpatient service. These patients were divide into group A (33 cases) and B(32 cases). Group A was treated with joint venture entecavier and group B was treated with domestic ones. all patients were given 0.5 mg daily and treated for 48 weeks. The cost-minimization analysis was made between two groups. Results ALT recovery rate, HBV-DNA negative conversion rate and HBeAg serum conversion rate had no statistically significant between two groups (P>0.05), but the cost of group A was 12 028.8, and the cost of group B was 7 996.8. Conclusions The domestic entecavier was better than the joint venture entecavier in treating the patients with chronic hepatitis B by cost-minimization analysis.
-
Key words:
- chronic hepatitis B /
- joint venture /
- domestic /
- entecavier /
- cost-minimization analysis
-
[1] 拉米夫定临床应用专家.2004年拉米夫定临床应用专家组共识[J].中华肝脏病杂志,2004,12(7):425. [2] 中华医学会肝病学分会、中华医学会感染病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881. [3] 冯 璇,童东梅,徐 翔.三种钙通道阻滞剂治疗高血压的费用效果-分析[J].中国临床药理学与治疗学,2001,6(3):233. [4] 顾 海,李洪超.药物经济学成本-效果分析应用的相关问题探讨[J].中国药房,2004,15(11):674. [5] 赵 东,朱玉霞.三种降压药物治疗方案的成本-效果分析[J].中国医院药学杂志 2005,25(8):753. [6] 刘林华,陈新月.抗乙型肝炎病毒新药-恩替卡韦[J].国际流行病学传染病学杂志,2006,33(1):58.
计量
- 文章访问数: 2264
- HTML全文浏览量: 255
- PDF下载量: 379
- 被引次数: 0